. . . . . . . . "Excretion is almost totally urinary; the main biotransformation product is Metabolite V. Essentially no parent drug is found in the urine."@en . "# : European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol. 1996;36(5):315-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8864715"@en . . "0.4-0.8 hours"@en . . . . "70%"@en . . . "Pentoxifylline"@en . . . . . . . . . . "Pentoxifyllin"@en . . . "Pentoxifyllinum"@en . . . "Humans and other mammals"@en . "investigational"@en . "LD₅₀=1385 mg/kg(orally in mice)"@en . . . . . . . . "Pentoxifilina"@en . . . . . . . . . "Pentoxil"@en . . "Trental"@en . . . . . . . . . . . . . . . "A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem]"@en . . . . . . "Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist."@en . . . . . . . . "For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs."@en . "Pentoxifylline"@en . . . . . . . "approved"@en . . "Take with food to reduce irritation. Limit caffeine intake."@en . . . . . . . . . . . . . . . . . . . . . . . . . " "@en . . . . . . "6493-05-6"@en . . . "Oxpentifylline"@en . .